Pneumonia is a respiratory disease characterized by inflammation of air sacs in lungs due to bacterial or viral infection.
The emergence of advanced diagnostic techniques to be one of the primary factors fueling the growth of the pneumonia therapeutics market in the coming years.

The global Pneumonia Therapeutics market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Pneumonia Therapeutics volume and value at global level, regional level and company level. From a global perspective, this report represents overall Pneumonia Therapeutics market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Pneumonia Therapeutics in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Pneumonia Therapeutics manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The following manufacturers are covered:
GlaxoSmithKline
Merck Sharp & Dohme
Novartis
Pfizer
AstraZeneca
Bayer
Biotest
Tetraphase Pharmaceuticals

Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India

Segment by Type
Vaccines
Anti-Infectives
Oxygen Therapy

Segment by Application
Hospital
Clinic
Medical Center
Other